Krystal Biotech reports Q1 EPS $1.20 vs 3c last year

Reports Q1 revenue $88.183M, consensus $96.21M. “We were thrilled to receive VYJUVEK approval in Europe, and with the potential expansion to Japan later in the year, we continue to make tremendous progress on our goal of delivering profound long-term benefit to DEB patients around the world,” said Krish Krishnan, Chairman and CEO of Krystal Biotech (KRYS). “With today’s announcement of our second clinical-stage ophthalmology program, the near-term initiation of our registrational study in DEB patients with eye lesions, and upcoming molecular readouts for our rare respiratory disease product candidates, KB407 and KB408, we are pushing forward a broad and expanded pipeline which we expect will ultimately demonstrate the power of HSV-1 based gene delivery in the lung, eye, and skin, and – most importantly – deliver meaningful benefit to patients.”